Express | 50% of patients' blood glucose levels reach normal levels, and Eli Lilly’s innovative treatment for diabetes reaches phase 3 clinical endpoint

▎The content team editor of WuXi AppTec today, Eli Lilly and Company announced that its glucose-dependent insulin-promoting polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist tirzepatide, named SURPASS- 2 reached the primary endpoint in phase 3 clinical trials.

Compared with the active control group, the three different doses of tirzepatide significantly reduced the glycosylated hemoglobin (A1C) level and body weight of patients with type 2 diabetes.

In the group of patients who received the highest dose (15 mg), after 40 weeks of treatment, 50% of the patients had A1C levels that reached the level of normal people, and the average weight was reduced by 12.
4 kg.

Previously, tirzepatide had reached the primary endpoint in two phase 3 clinical trials.

Tirzepatide is one of the key development projects that Eli Lilly has high hopes for.
It is a GIP and GLP-1 receptor dual agonist injected once a week, which can integrate the effects of two incretins into one molecule.
It represents a new type of treatment for type 2 diabetes.

GIP is a hormone that may complement the effects of GLP-1 receptor agonists.

In preclinical models, GIP has been shown to reduce food intake and increase energy expenditure, thereby causing weight loss.
When used in combination with GLP-1 receptor agonists, it may have a greater impact on glucose levels and weight.

In this randomized open-label clinical trial, a total of 1,879 type 2 diabetic patients received tirzepatide or injectable semaglutide (semaglutide, 1 mg) in addition to metformin.

These patients had an average history of diabetes of 8.
6 years, and the use of metformin alone did not allow their blood sugar levels to be adequately controlled.The test results showed that, compared with the active control group, the three different doses (5 mg, 10 mg, and 15 mg) of tirzepatide all caused a greater degree of A1C and weight loss.
The specific values ​​are as follows.

In the group of patients treated with tirzepatide at a dose of 15 mg.

92% of patients have A1C levels below 7%, which is the standard recommended by the American Diabetes Association for diabetic patients.

The A1C level of 50.
9% of patients was lower than 5.
7%, which is the standard for healthy people without diabetes.

▲Efficacy data of Tirzepatide in the SURPASS-2 clinical trial (data source: reference [1], drawing by WuXi AppTec's content team) "In the United States, nearly 90% of patients with type 2 diabetes are obese or overweight.

We are committed to Develop innovative solutions that can not only reduce A1C, but also significantly reduce weight to meet their needs.

"Mike Mason, President of Eli Lilly Diabetes, said, "These amazing clinical results exceed our expectations and support three different doses of tirzepatide.
It may become a potential new treatment option for patients with type 2 diabetes.

"Note: This article is intended to introduce medical health research, not a treatment plan recommendation.

If you need guidance on treatment plans, please go to a regular hospital for treatment.

Reference: [1] Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes.
Retrieved March 4, 2021, from https://investor.
lilly.
com/news-releases/ news-release-details/tirzepatide-achieved-superior-a1c-and-body-weight-reductions